The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID.
Jingwei LiYun ZhouJiechao MaQin ZhangJun ShaoShufan LiangYizhou YuWei-Min LiChengdi WangPublished in: Signal transduction and targeted therapy (2023)
There have been hundreds of millions of cases of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the growing population of recovered patients, it is crucial to understand the long-term consequences of the disease and management strategies. Although COVID-19 was initially considered an acute respiratory illness, recent evidence suggests that manifestations including but not limited to those of the cardiovascular, respiratory, neuropsychiatric, gastrointestinal, reproductive, and musculoskeletal systems may persist long after the acute phase. These persistent manifestations, also referred to as long COVID, could impact all patients with COVID-19 across the full spectrum of illness severity. Herein, we comprehensively review the current literature on long COVID, highlighting its epidemiological understanding, the impact of vaccinations, organ-specific sequelae, pathophysiological mechanisms, and multidisciplinary management strategies. In addition, the impact of psychological and psychosomatic factors is also underscored. Despite these crucial findings on long COVID, the current diagnostic and therapeutic strategies based on previous experience and pilot studies remain inadequate, and well-designed clinical trials should be prioritized to validate existing hypotheses. Thus, we propose the primary challenges concerning biological knowledge gaps and efficient remedies as well as discuss the corresponding recommendations.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- clinical trial
- systematic review
- end stage renal disease
- ejection fraction
- physical activity
- quality improvement
- intensive care unit
- hepatitis b virus
- depressive symptoms
- acute respiratory distress syndrome
- sleep quality
- respiratory failure
- drug induced
- phase iii
- open label